Eisai Secures Exclusive Rights to Serplulimab in Japan for $388M+ Deal — Shanghai Henlius Biotech, Inc.

Event summary

Henlius licenses exclusive commercial rights for serplulimab in Japan to Eisai for $75M upfront, with potential milestone payments reaching $388.32M.
Serplulimab is the world's first anti-PD-1 antibody approved as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC).
Henlius will conduct additional clinical trials in Japan for non-MSI-High metastatic colorectal cancer and perioperative gastric cancer.
Eisai anticipates no changes to its consolidated financial forecast for the fiscal year ending March 31, 2026.

The big picture

This deal underscores the growing importance of anti-PD-1 therapies in global oncology markets, particularly in Japan where unmet medical needs are significant. The collaboration between Henlius and Eisai highlights a trend of international biopharmaceutical partnerships aimed at accelerating drug development and market access. With serplulimab's unique binding mode and first-line approval for ES-SCLC, this agreement could set a precedent for future licensing deals in the anti-PD-1 space.

What we're watching

Regulatory Approval: Whether Henlius can secure regulatory approval for serplulimab in Japan by fiscal year 2026 based on ongoing Phase II bridging clinical trial results.
Market Penetration: The pace at which Eisai can commercialize serplulimab in Japan, addressing high unmet medical needs for ES-SCLC and non-MSI-High metastatic colorectal cancer.
Revenue Impact: How the potential milestone payments and royalties will affect Henlius's financial performance and Eisai's long-term strategic positioning in the oncology market.